

Date of preparation: 2022-01-14

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Mabion receives an additional order for the production of cellular banks under the manufacturing agreement with Novavax, Inc.

Legal basis: Article 17 (1) of MAR – confidential information

Content of the Report:

With reference to Current Reports no. 52/2021 of 8 October 2021 regarding the conclusion of a commercial contractual production agreement (“Manufacturing Agreement”) with Novavax, Inc. (“Novavax”), the Management Board of Mabion S.A. (“Company”) hereby informs that on 14 January 2022, under the Manufacturing Agreement, the parties signed another additional order in the form of a Statement of Work #3 (“SOW#3”).

Under SOW#3 currently in force, in addition to the existing work, the Company will produce cell banks for Novavax in accordance with the Good Manufacturing Practice (GMP) standard, and said banks will be used as the key biological material that forms the manufacturing base for the vaccine antigens of the Nuvaxovid product. The production will be carried out in accordance with the technical and quality requirements defined in SOW#3. The project will be implemented in the first quarter of 2022 and the resulting prepared cell banks, after a series of analytical tests, will be made available to Novavax as part of the existing network of entities involved in the production of the Nuvaxovid vaccine.

Despite the fact that, in relation to the originally signed Manufacturing Agreement, the financial value of SOW#3 itself is not significant for the assessment of the significance of the order for the Company, the extension of the cooperation with Novavax to another new area, i.e. production of cell banks, remains an important and key business value for the Company. Moreover, the event described herein involves major operational activity aimed at increasing the vaccine production capacity by Novavax. The selection of the Company in the tender procedure carried out by the contractor once again confirms the Company's credentials as a Contract Development and Manufacturing Organization (CDMO).